[Radiation therapy for brain tumors].

Yoshiaki Tanaka, Motoaki Fujii, Tsutomu Saito, Jiro Kawamori
{"title":"[Radiation therapy for brain tumors].","authors":"Yoshiaki Tanaka,&nbsp;Motoaki Fujii,&nbsp;Tsutomu Saito,&nbsp;Jiro Kawamori","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Brain tumors respond differently to treatment with surgery plus radiotherapy or radiotherapy alone, combined with or without chemotherapy, because they are characterized by subtypes with different histologies. Since the development of diagnostic radiology, such as computed tomography (CT) and magnetic resonance imaging (MRI), brain tumors have been easier to demonstrate and can be found at earlier stages than in the conventional situation. Furthermore, highly technical devices and equipment for radiation therapy have been developed and installed for clinical use, especially with multileaf collimator (MLC) and treatment planning systems. In the field of radiotherapy for brain tumors, it has been possible to use more precise treatment planning with conformal radiotherapy, three-dimensional treatment planning, and stereotactic radiotherapy. Dose escalation studies and the modified fractionation schedule of radiotherapy can also be designed by analyzing biological data and applying hypofractionated intensity-modulated radiotherapy (IMRT) to radioresistant tumors such as glioblastoma multiforme and anaplastic astrocytoma. Future investigation may be useful to determine which fraction size is likely to be optimal for these malignant gliomas when highly conformal radiotherapy is used in adjuvant treatment. These technological developments and newly designed radiosensitizing agents will improve local control rates and survival times, thereby enhancing the quality of life in patients suffering from various kinds of brain tumors.</p>","PeriodicalId":19251,"journal":{"name":"Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica","volume":"64 7","pages":"387-93"},"PeriodicalIF":0.0000,"publicationDate":"2004-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Brain tumors respond differently to treatment with surgery plus radiotherapy or radiotherapy alone, combined with or without chemotherapy, because they are characterized by subtypes with different histologies. Since the development of diagnostic radiology, such as computed tomography (CT) and magnetic resonance imaging (MRI), brain tumors have been easier to demonstrate and can be found at earlier stages than in the conventional situation. Furthermore, highly technical devices and equipment for radiation therapy have been developed and installed for clinical use, especially with multileaf collimator (MLC) and treatment planning systems. In the field of radiotherapy for brain tumors, it has been possible to use more precise treatment planning with conformal radiotherapy, three-dimensional treatment planning, and stereotactic radiotherapy. Dose escalation studies and the modified fractionation schedule of radiotherapy can also be designed by analyzing biological data and applying hypofractionated intensity-modulated radiotherapy (IMRT) to radioresistant tumors such as glioblastoma multiforme and anaplastic astrocytoma. Future investigation may be useful to determine which fraction size is likely to be optimal for these malignant gliomas when highly conformal radiotherapy is used in adjuvant treatment. These technological developments and newly designed radiosensitizing agents will improve local control rates and survival times, thereby enhancing the quality of life in patients suffering from various kinds of brain tumors.

[脑肿瘤的放射治疗]。
脑肿瘤对手术加放疗或单独放疗、联合化疗或不联合化疗的反应不同,因为它们的特点是具有不同组织学的亚型。自从计算机断层扫描(CT)和磁共振成像(MRI)等诊断放射学发展以来,脑肿瘤比传统情况下更容易在早期阶段被发现和证实。此外,已经开发和安装了用于放射治疗的高技术装置和设备,以供临床使用,特别是多叶准直仪和治疗计划系统。在脑肿瘤放射治疗领域,已经可以使用更精确的治疗计划,如适形放疗、三维治疗计划和立体定向放疗。通过分析生物学数据,并将低分割调强放疗(IMRT)应用于多形性胶质母细胞瘤和间变性星形细胞瘤等放射耐药肿瘤,也可以设计剂量递增研究和改进的放疗分割计划。未来的研究可能有助于确定当高度适形放疗用于辅助治疗时,哪种分数大小可能是这些恶性胶质瘤的最佳选择。这些技术发展和新设计的放射增敏剂将提高局部控制率和生存时间,从而提高各种脑肿瘤患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信